Please assess the completion status of the following clinical trial:

Trial Title: Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Immunocompromised state due to either 1. receipt of hematopoeitic stem cell transplantation or 2. hematologic malignancy;~* Diagnosis of possible, probable, or proven invasive aspergillosis.~Exclusion Criteria:~* Patients with aspergilloma or chronic aspergillosis~* Receipt of 4 or more days of systemic antifungal treatment for the current episode of invasive aspergillosis~* Anticipated survival of less than 5 days or Karnofsky score \<=20

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Voriconazole (Type: ACTIVE_COMPARATOR): Voriconazole monotherapy
- Voriconazole and Anidulafungin (Type: EXPERIMENTAL): Combination therapy with voriconazole and anidulafungin

Based on this trial design, predict the completion outcome and termination type (if applicable).